Compound having antitumor activity against cancer cells having exon 20 mutation of EGFR or HER2

摘要

The present disclosure provides for treating cancer in a patient determined to have an exon 20 mutation (eg, an insertion mutation) in EGFR and / or HER2 by administering a third generation tyrosine kinase inhibitor, such as podiotinib or afatinib. Provide a way.